Folic Acid Dosing and Safety Guidelines

Standard Dosing for Deficiency Treatment

Oral folic acid 5 mg daily for at least 4 months until biochemical correction of deficiency is achieved【3】.
Prior to initiating folic acid, vitamin B12 deficiency must be excluded to prevent subacute combined degeneration of the spinal cord【3】.
After correction, maintenance dosing is 330 µg dietary folate equivalents (DFE) per day for non‑pregnant adults and 600 µg DFE per day for pregnant or lactating women【2】.

All women of child‑bearing potential should receive 0.4 mg (400 µg) folic acid daily periconceptionally and continue while capable of becoming pregnant【4】.
Women with a previous NTD‑affected pregnancy should receive 4 mg folic acid daily when planning conception【4】【6】.

Folic acid 5 mg administered weekly to daily reduces mucosal, gastrointestinal, and hepatotoxic adverse effects of methotrexate【7】.
Folate supplementation should not be taken on the same day as methotrexate to avoid competitive cellular uptake【8】.

When oral intake is ineffective or not tolerated, 0.1 mg folic acid may be given subcutaneously, intravenously, or intramuscularly daily【11】.

Folate supplementation must never precede exclusion of vitamin B12 deficiency, as folic acid can correct hematologic abnormalities while neurological damage continues【3】.
The unsupervised upper limit for folic acid is 1 mg per day to minimize the risk of masking vitamin B12 deficiency【1】【11】.
Total daily folate intake should remain below 1 mg unless under medical supervision【4】.
The lowest observed adverse effect level (LOAEL) for folic acid is set at 5 mg per day【1】.

Baseline folate status should be measured, with repeat testing within 3 months of supplementation to confirm normalization【1】【5】.
In conditions with increased folate requirements, monitoring should occur every 3 months until levels stabilize, then annually【1】【5】.
Target serum folate concentration is ≥10 nmol/L and red‑blood‑cell folate ≥340 nmol/L【1】.